OP0312 International league of associations for rheumatology (ILAR) treatment recommendations for psoriatic arthritis in resource-poor countries
Authors: M. Elmamoun, M. Eraso, A. Maharaj, V. Chandran, L. Coates, A Adebajo, A Sharma, S Toloza, L Vega-E, O Vega-H, A Abogamal, A Ajibade, O Ayanlowo, V Azevedo, W Bautista-M, S Carneiro, C Goldenstein-S, F Hernandez-V, U Ima-E, A Lima, J Medina-R, G Mody, T Narang, A Ortega-L, R Ranza
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) updated their respective recommendations for the management of PsA in 2015. However, these guidelines are primarily based on studies conducted in resource replete countries; hence they may not be applicable to countries in Central and South America, and Africa. Therefore, new ILAR recommendations have been developed for these regions adapted from existing recommendations. <h3>Objectives</h3> To establish ILAR recommendations for the management of PsA in resource poor settings, particularly Central/South America and Africa, using an expert local panel, adaptation of existing EULAR and GRAPPA treatment recommendations and a new systematic literature review (SLR) for specific issues in resource-poor countries. <h3>Methods</h3> The ADAPTE Collaboration process<sup>1</sup> for guideline adaptation was followed to assess and adapt the EULAR and GRAPPA treatment recommendations for PsA covering the Americas and Africa. The process was conducted according to its three phases: set-up phase (identifying and seeing agreement from a panel of participants from the relevant countries), adaptation phase (defining health questions using the PIPOH tool, assessing the two source recommendations, conducting an SLR to answer health questions not addressed in the two source recommendations, assessing quality of source recommendations, assessing applicability of principles contained in the source recommendations, and drafting adapted recommendations), and finalisation phase (external review, aftercare planning and final production). <h3>Results</h3> Five principles for the management of PsA were developed addressing 1. Goals of therapy, 2. Assessment of domains, 3. Assessment of relevant comorbidities, 4. Safety of pharmacotherapy and shared decision making, and 5. Frequency of follow up. Six recommendations for the management of PsA were also developed addressing 1. Goals of therapy, 2. Screening and management of tuberculosis, HIV, HBV, HCV, Chagas’ disease, leishmaniasis, leprosy, and other concomitant comorbidities, 3. Frequency of monitoring in resource poor countries, 4. Safety and efficacy of pharmacotherapy in all domains, 5. Efficacy and safety of combination therapy, and 6. Safety and efficacy of biosimilars and intended copies. <h3>Conclusions</h3> ILAR recommendations for the management of PsA in resource-poor countries are now available, developed by adapting principally the GRAPPA recommendations, but also the EULAR recommendations, supplemented by expert opinion from these regions. <h3>Reference</h3> [1] The ADAPTE Collaboration. The ADAPTE Process: Resource Toolkit for Guideline Adaptation<i>, Version 2.0</i> 2009. [Available from] http://wwwg-i-n.net <h3>Disclosure of Interest</h3> None declared